[1] |
LI Min, LI Chunlei, SUN Cuicui, YU Wenwen, SUN Qing, QI Yingmei, LIU Anchang.
One Case of Acute Generalized Exanthematous Pustulosis Caused by Abrocitinib Tablets
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 823-825.
|
[2] |
GAO Xu, PENG Jin’e, FAN Zibo, ZHANG Wei.
Systematic evaluation of clinical features and prognostic outcomes of rifampicin-induced hemolytic anemia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 671-676.
|
[3] |
JI Qiuxia, JIN Jian, ZHANG Bin.
Pharmaceutical care for immune-related adverse events induced by toripalimab
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.
|
[4] |
GUO Ningzi, LIU Li, YUE Ruiqi, FENG Huiqing, YANG Huaxin, WEI Ningyi, CHEN Hua.
Determination of particle size distribution of chiglitazar sodium by laser diffraction method
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 147-151.
|
[5] |
GUO Yijun, CHEN Xia, MENG Ping.
Adverse drug reaction reports in 141 cases of orally administered targeted anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1137-1142.
|
[6] |
LIU Meng, FANG Ke, YAN Jiaju, LIU Meng, HE Manyun, WEI Liangbing.
One case of anaphylactic shock caused by pamidronate disodium glucose injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1172-1174.
|
[7] |
LIU Saiyue, LYU Xiaoqin, ZHOU Yun.
Key points of investigation and report of suspected death of adverse drug reaction
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
|
[8] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[9] |
WU Yanyan, HU Xuelian, DAN Chonghui.
Analysis of one case of double knee joint pain induced by linezolid tablets
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 221-224.
|
[10] |
ZHUANG Hongyan, ZANG Yannan, LIU Shanshan, NIU Mengxi, FANG Meng, YIN Dongqing, GUO Wei.
Analysis of neuropsychiatric adverse reactions caused by zolpidem
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 889-892.
|
[11] |
ZHANG Xi, LI Pengfei, ZHAO Jie, LIU Lihong.
162 reports of adverse drug reactions induced by omeprazole sodium for injection
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 287-291.
|
[12] |
ZHU Lan, ZHU Yan, YAO Keyu, CHEN Chao, LIU Lihong.
Analysis of data elements in case reports of traditional Chinese medicine drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1352-1357.
|
[13] |
ZHANG Haifei, YU Shanshan, CAO Jin, ZHANG Tianzhu, WU Dongkai, NI Yike, ZUO Conglin, HU Xiaomin.
Features and Requirements of Non-clinical Toxic Evaluation of Inhalable Drugs
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 570-574.
|
[14] |
ZHANG Xiaowen, LIU Jianping.
Introduction and Application of Standardization of case Reports on Drug Safety
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 459-463.
|
[15] |
LI Hui, WANG Dandan, YANG Han, ZHANG Xuenong.
Research Progress on Drug-loaded Albumin Nanoparticles
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 636-642.
|